ConductScience.org, home

Paper2736709

Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.

Cao SS and 1 other. Cancer Chemother Pharmacol, 1989. Cited by 72 papers, by iCite.

Cite this record

ConductScience Library. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Papers, record 2736709. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2736709

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1989
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
1.52
iCite
Revised in PubMed
2022-03-16
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cao SSS S
2Zhen YSY S

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Amphotericin BMajor topic
Antimetabolites, AntineoplasticMajor topic
DipyridamoleMajor topic
Animals
Drug Evaluation, Preclinical
Drug Synergism
Drug Therapy, Combination
Female
Fluorouracil
Lung Neoplasms
Male
Methotrexate
Mice
Mice, Inbred C57BL
Neoplasm Transplantation
Sarcoma 180
Uterine Cervical Neoplasms

Source PubMed

Download CSV of topics

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14038918Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line.Cancer Treat Rep1985https://conductscience.org/library/papers/4038918PubMed
2272228Clinical, biological, and biochemical effect of pyrazofurin.Cancer Res1978https://conductscience.org/library/papers/272228PubMed
35899044[A comparison of the destructive effects of five antitumour agents on various normal tissues in mice].Yao Xue Xue Bao1965https://conductscience.org/library/papers/5899044PubMed
43778458Amphotericin B renders stationary phase hepatoma cells sensitive to dipyridamole.Biochem Biophys Res Commun1986https://conductscience.org/library/papers/3778458PubMed
56305486Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.Cancer Res1983https://conductscience.org/library/papers/6305486PubMed
63542142Advances in rational combination chemotherapy.Cancer Invest1986https://conductscience.org/library/papers/3542142PubMed
76119898Chemotherapeutic inhibitors of the enzymes of the de novo pyrimidine pathway.Adv Pharmacol Chemother1981https://conductscience.org/library/papers/6119898PubMed
83673709Salvage pathways as targets of chemotherapy.Adv Enzyme Regul1987https://conductscience.org/library/papers/3673709PubMed
96243243Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.Cancer1980https://conductscience.org/library/papers/6243243PubMed
1019971022Response of the Gastrointestinal Tract of the Mouse to 5-Fluorouracil.Am J Pathol1963https://conductscience.org/library/papers/19971022PubMed
117396898Amphotericin B (Fungizone R) enhancement of nitrogen mustard uptake by human tumor cells.Biochem Biophys Res Commun1980https://conductscience.org/library/papers/7396898PubMed
126744269Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole.Cancer Res1984https://conductscience.org/library/papers/6744269PubMed
134016741Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.Cancer Res1985https://conductscience.org/library/papers/4016741PubMed
146825115Effects of amphotericin B on adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and in L1210 leukemia.Cancer Res1983https://conductscience.org/library/papers/6825115PubMed
156586287Potentiation of methotrexate toxicity by dipyridamole.Cancer Res1984https://conductscience.org/library/papers/6586287PubMed
167060316Dipyridamol kinetics.Clin Pharmacol Ther1982https://conductscience.org/library/papers/7060316PubMed
17277727Growth and rejection of leukemia cells in individual mice after combined treatment with amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea.J Natl Cancer Inst1978https://conductscience.org/library/papers/277727PubMed
183675621Amphotericin B: a biological response modifier in targeting against the salvage pathways.Biochem Pharmacol1987https://conductscience.org/library/papers/3675621PubMed
196443595Salvage capacity of hepatoma 3924A and action of dipyridamole.Adv Enzyme Regul1983https://conductscience.org/library/papers/6443595PubMed
206589439Amphotericin B potentiation of the cytotoxicity of anticancer agents against both normal hematopoietic and leukemia cells in mice.J Natl Cancer Inst1984https://conductscience.org/library/papers/6589439PubMed

See all 27 referencesDownload CSV of references

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
41565692Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1.NPJ Vaccines2026https://conductscience.org/library/papers/41565692PubMed
37138847Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer.Front Pharmacol2023https://conductscience.org/library/papers/37138847PubMed
37026480Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy.Nucleic Acids Res2023https://conductscience.org/library/papers/37026480PubMed
36963401Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.Cancer Cell2023https://conductscience.org/library/papers/36963401PubMed
36382671Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin.Int J Oncol2023https://conductscience.org/library/papers/36382671PubMed
36189423Functional high-throughput screen identifies microRNAs that promote butyrate-induced death in colorectal cancer cells.Mol Ther Nucleic Acids2022https://conductscience.org/library/papers/36189423PubMed
35835838Co-inhibition of ATM and ROCK synergistically improves cell proliferation in replicative senescence by activating FOXM1 and E2F1.Commun Biol2022https://conductscience.org/library/papers/35835838PubMed
35456598NMS-873 Leads to Dysfunctional Glycometabolism in A p97-Independent Manner in HCT116 Colon Cancer Cells.Pharmaceutics2022https://conductscience.org/library/papers/35456598PubMed
35118769An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.Cancer Sci2022https://conductscience.org/library/papers/35118769PubMed
34899683Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages.Front Immunol2021https://conductscience.org/library/papers/34899683PubMed
34493732Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer.Nat Commun2021https://conductscience.org/library/papers/34493732PubMed
33562636Integrative Transcriptomic Network Analysis of Butyrate Treated Colorectal Cancer Cells.Cancers (Basel)2021https://conductscience.org/library/papers/33562636PubMed
33388950Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation.Cancer Chemother Pharmacol2021https://conductscience.org/library/papers/33388950PubMed
33203790Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.Aging (Albany NY)2020https://conductscience.org/library/papers/33203790PubMed
33115525Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia.J Exp Clin Cancer Res2020https://conductscience.org/library/papers/33115525PubMed
32575795Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.Molecules2020https://conductscience.org/library/papers/32575795PubMed
32433558Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids.Cell Death Differ2020https://conductscience.org/library/papers/32433558PubMed
31950222Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice.Naunyn Schmiedebergs Arch Pharmacol2020https://conductscience.org/library/papers/31950222PubMed
31289488Ampelopsin-sodium induces apoptosis in human lung adenocarcinoma cell lines by promoting tubulin polymerization in vitro.Oncol Lett2019https://conductscience.org/library/papers/31289488PubMed
29920512Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.PLoS Comput Biol2018https://conductscience.org/library/papers/29920512PubMed

See all 38 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2736709

GET https://conductscience.org/api/papers/v1/2736709/references?page=2